The Board of Directors of Aurinia Pharmaceuticals Inc. has authorized a buyback plan on February 15, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.435 USD | -0.46% | +1.09% | -39.50% |
Jun. 05 | Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis | CI |
Jun. 03 | Lucien Selce Sends Letter to Aurinia shareholders | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.50% | 779M | |
+18.47% | 125B | |
+14.06% | 109B | |
-2.98% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-11.92% | 16.64B | |
0.00% | 13.45B | |
+22.53% | 11.32B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. authorizes a Buyback Plan.